194 completed, 55 terminated, 51 recruiting, 35 unknown. 395 Phase 2, 94 Phase 1, 34 Phase 3.
Follow Hemoglobinopathies: new trials by email Literature Review of Hemoglobinopathies trials Research Report on Hemoglobinopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility and Acceptability of Amani Amani - Sickle Cell Disease | Phase 1 / Phase 2 | Not yet recruiting | Massachusetts General Hospital | 40 | 2026-11-01 | 2026-08-07 |
| Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype Senicapoc, Placebo - Sickle Cell Disease, Sickle Cell Anaemia | Phase 2 | Recruiting | Biossil Inc. | 65 | 2026-11-01 | 2026-11-02 |
| Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion - Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 2 | Recruiting | Mohsen Saidinejad | 120 | 2026-09-10 | 2026-09-02 |
| Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease Cyclophosphamide 50mg, Abatacept, Alemtuzumab - Sickle Cell Disease | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 45 | 2026-09-10 | 2026-11-12 |
| Gene Therapy for Patients With Transfusion-Dependent β-Thalassemia HGI-001 Injection - Beta Thalassemia Transfusion Dependent | Phase 2 | Not yet recruiting | Prince of Wales Hospital, Shatin, Hong Kong | 6 | 2026-09-01 | 2026-07-23 |
| Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs - Bone Marrow Failure, Hemoglobinopathies | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 40 | 2026-09-01 | 2026-06-22 |
| Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors Total Body Irradiation, Alemtuzumab, Abatacept - Sickle Cell Disease, Beta-thalassemia | Phase 1 / Phase 2 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 90 | 2026-07-08 | 2026-10-13 |
| Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation Intravenous Immunoglobulin, Dexamethasone, Mononuclear Cells - Leukemia, Lymphoma | Phase 2 | Not yet recruiting | Hematology department of the 920th hospital | 60 | 2026-07-03 | 2026-07-14 |
| A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT) SNH-119014 dose 1, SNH-119014 dose 2, Placebo - Thalassemia | Phase 2 | Recruiting | ScinnoHub Pharmaceutical Co., Ltd. | 30 | 2026-06-16 | 2026-11-19 |
| Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease Ruxolitinib - Sickle Cell Disease, Hematopoetic Stem Cell Transplant | Phase 1 / Phase 2 | Recruiting | Arkansas Children's Hospital Research Institute | 24 | 2026-06-08 | 2026-06-04 |
| STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE Plerixafor Dose Escalation - Sickle Cell Disease | Phase 1 / Phase 2 | Not yet recruiting | Hospital Israelita Albert Einstein | 12 | 2026-06-01 | 2026-01-14 |
| Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study hydroxycarbamide - Sickle Cell Disease, Sickle Cell Anemia in Children | Phase 1 / Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 250 | 2026-05-13 | 2026-07-16 |
| Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin Empagliflozin (oral) - Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria | Phase 2 | Recruiting | University of Illinois at Chicago | 20 | 2026-04-08 | 2026-05-19 |
| Open-Label Extension Study to Pioneer Study 6058-SCD-101 Pociredir - Sickle Cell Disease | Phase 2 | Terminated | Fulcrum Therapeutics | 1 | 2026-03-30 | 2026-10-28 |
| Alendronate for Osteonecrosis in Adults With Sickle Cell Disease Alendronate Sodium - Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Recruiting | University of California, Davis | 30 | 2026-03-09 | 2026-07-16 |
| A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy Mitapivat - Sickle Cell Disease, Nephropathy | Phase 2 | Withdrawn | Agios Pharmaceuticals, Inc. | 2026-03-01 | 2026-04-03 | |
| Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA. DREAM01 drug product, anti-inflammatory therapy - Sickle Cell Disease | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 15 | 2026-02-25 | 2026-03-04 |
| Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial 25 mg/day zinc, 40 mg/day zinc - Sickle Cell Disease | Phase 2 | Recruiting | University of California, San Francisco | 34 | 2026-02-14 | 2026-03-13 |
| Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia Pharmacokinetic based dosage change, Pharmacokinetic dosing - Sickle Cell Disease (SCD) | Phase 2 / Phase 3 | Recruiting | Yves Pastore | 29 | 2026-02-03 | 2026-08-21 |
| Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) Anumigilimab, Placebo - Sickle Cell Disease | Phase 2 | Recruiting | CSL Behring | 63 | 2026-02-02 | 2026-11-03 |
Showing 20 of 395. Sign in to see all of them.
Anemia, Sickle Cell (293) · beta-Thalassemia (87) · Thalassemia (71) · Vaso-Occlusive Crises (27) · Anemia (24) · Iron Overload (21) · Anemia, Diamond-Blackfan (18) · Hematologic Diseases (17) · Genetic Diseases, Inborn (16) · Anemia, Aplastic (13) · Bone Marrow Failure Disorders (13) · Acute Chest Syndrome (10) · Myelodysplastic Syndromes (10) · Anemia, Hemolytic (9)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (394) · Hemic and Lymphatic Diseases (394) · Anemia, Hemolytic, Congenital (382) · Genetic Diseases, Inborn (379) · Hematologic Diseases (378) · Anemia, Hemolytic (377) · Anemia (365) · Thalassemia (67) · Pathological Conditions, Signs and Symptoms (48) · Nutritional and Metabolic Diseases (46) · Metabolic Diseases (38) · Bone Marrow Diseases (35) · Immune System Diseases (30) · Pathologic Processes (30)
Hydroxyurea (44) · Alemtuzumab (26) · Cyclophosphamide (25) · Deferasirox (22) · Sirolimus (22) · fludarabine (21) · Busulfan (19) · fludarabine phosphate (18) · Whole-Body Irradiation (17) · Deferoxamine (12) · Mycophenolic Acid (11) · Tacrolimus (10) · thymoglobulin (10) · Melphalan (9) · Antilymphocyte Serum (8)
Novartis Pharmaceuticals (19) · National Heart, Lung, and Blood Institute (NHLBI) (18) · St. Jude Children's Research Hospital (10) · Assistance Publique - Hôpitaux de Paris (8) · Children's Hospital Medical Center, Cincinnati (8) · UCSF Benioff Children's Hospital Oakland (8) · Emory University (6) · University of North Carolina, Chapel Hill (6) · Ain Shams University (5) · Baylor College of Medicine (5) · Johns Hopkins University (5) · New York Medical College (5) · University of Illinois at Chicago (5) · Agios Pharmaceuticals, Inc. (4) · Boston University (4)
United States (265) · United Kingdom (45) · Italy (38) · Canada (36) · Lebanon (32) · France (30) · Turkey (Türkiye) (25) · Greece (18) · Thailand (18) · Egypt (14) · China (13) · Brazil (12) · Kenya (10) · Nigeria (10) · Germany (9)
Claudia Morris, MD (4) · John F Tisdale, M.D. (4) · Kenneth I Ataga, MD (4) · Damiano Rondelli, MD (3) · Mark Walters (3) · Mitchell S Cairo, MD (3) · Russell Ware, MD, PhD (3) · Shalini Shenoy, MD (3) · A O Dosunmu, M.D. (2) · Ahmed F Mahmoud Hussein, MS.c (2)
PMID 36240296, PMID 37975597, PMID 42133908, PMID 34175041, PMID 37254256, PMID 26348869, PMID 38775255, PMID 40569673, PMID 29931453, PMID 32384147, PMID 33283989, PMID 34922648, PMID 36355805, PMID 36529836, PMID 36860093, PMID 36975201, PMID 38866240, PMID 40010689, PMID 41026975, PMID 41809202, PMID 41871072, PMID 41954645, PMID 42224366, PMID 42549972, PMID 14550808, PMID 15592491, PMID 16990602, PMID 17233848, PMID 18026148, PMID 18192510, PMID 18500373, PMID 18550258, PMID 20007560, PMID 20421452, PMID 20955402, PMID 21173101, PMID 21275961, PMID 21364138, PMID 21393329, PMID 21477202, PMID 21527519, PMID 21700776, PMID 21742281, PMID 21900080, PMID 22129980, PMID 22251482, PMID 22571408, PMID 2265118, PMID 22875626, PMID 22887019
2018 (5), 2014 (4), 2023 (4), U01HL065238 (4), 2017 (3), 2019 (3), 2016 (2), 2025 (2), K24AT009893 (2), U24CA076518 (2), U54HL070587 (2), 1OT2HL154815 (1), 1UG3AT011265-01 (1), 2004 (1), 2015 (1)